FDA grants approval for Vanda Pharmaceuticals antipsychotic pill Bysanti
Vanda Pharma received FDA approval for its antipsychotic pill Bysanti today. The drug treats schizophrenia and bipolar disorder with a launch set for Q3.
Insights:
The U.S. Food and Drug Administration has approved the antipsychotic pill Bysanti (milsaperidone) from Vanda Pharmaceuticals Inc. for the treatment of schizophrenia and acute bipolar I disorder in the US 
US. The approval, which was announced on February 20, 2026, led to a roughly 30% rise in the company's shares during extended trading. This regulatory milestone marks a completed event that directly impacts Vanda's product lineup and its broader competitive positioning within the atypical antipsychotics / psychiatric drug market.
US. The approval, which was announced on February 20, 2026, led to a roughly 30% rise in the company's shares during extended trading. This regulatory milestone marks a completed event that directly impacts Vanda's product lineup and its broader competitive positioning within the atypical antipsychotics / psychiatric drug market.
